Jazz Pharmaceuticals plc - 8-K Filing
Jazz Pharmaceuticals extended maturity date of $1.895B term loan facility from May 2028 to May 2033 and reduced interest rate margin by 50 bps. (Items: 1.01 Entry into a Material Definitive Agreement, 2.03 of the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission (the “SEC”) on May 5, 2021, which description, 9.01 Financial Statements and Exhibits)
Tickers: $JAZZ